Kentaro Nishi1, Masao Ogura1, Sho Ishiwa1,2, Toru Kanamori1,3, Mika Okutsu1,3, Shunsuke Yokota1, Taishi Nada1, Mai Sato1, Koichi Kamei1, Kenji Ishikura1,4, Shuichi Ito5,6. 1. Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan. 2. Department of Pediatrics, Oita University, Faculty of Medicine, Oita, Japan. 3. Department of Pediatrics, Tokyo Medical and Dental University, Tokyo, Japan. 4. Department of Pediatrics, Kitasato University School of Medicine, Kanagawa, Japan. 5. Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan. itoshu@yokohama-cu.ac.jp. 6. Department of Pediatrics, Yokohama City University Graduate School of Medicine, 3-9, Fukuura, Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan. itoshu@yokohama-cu.ac.jp.
Abstract
BACKGROUND: Glucocorticoid discontinuation, a challenge in systemic lupus erythematosus (SLE), might be achievable with the advent of new therapeutic options. METHODS: This single-center study included 31 children with newly diagnosed pediatric SLE between 2002 and 2021, after the exclusion of patients who were followed for less than 1 year after treatment initiation and those lost to follow-up. Patient characteristics, clinical course including flares, treatment, glucocorticoid discontinuation, and outcomes were retrospectively analyzed. RESULTS: Glucocorticoids could be discontinued in 19 (61%) patients during a median observation period of 105.5 (range, 17-221) months. Of these, 5 (26%), 12 (63%), and 18 (95%) patients could discontinue glucocorticoids in 3, 5, and 10 years from treatment initiation, respectively. Additionally, 18 of the 19 patients did not experience flares after glucocorticoid discontinuation during a median duration of 37.2 (7.2-106.8) months. Three of the nineteen patients achieved drug-free remission. At last follow-up, all patients achieved low disease activity with or without glucocorticoids and 19, 8, and 1 patient were receiving mycophenolate mofetil (MMF), MMF plus tacrolimus, and MMF plus ciclosporin A, respectively. Flares were observed in 15 patients during the observation period. MMF as initial immunosuppressant (P = 0.01) and shorter interval between therapy initiation and achieving maintenance prednisolone dose of 0.1-0.15 mg/kg/day (P = 0.001) were associated with significantly reduced flare risk. Femoral head necrosis was observed in two patients. CONCLUSION: Despite the small sample size, these results support glucocorticoid discontinuation as a therapeutic target in pediatric SLE.
BACKGROUND: Glucocorticoid discontinuation, a challenge in systemic lupus erythematosus (SLE), might be achievable with the advent of new therapeutic options. METHODS: This single-center study included 31 children with newly diagnosed pediatric SLE between 2002 and 2021, after the exclusion of patients who were followed for less than 1 year after treatment initiation and those lost to follow-up. Patient characteristics, clinical course including flares, treatment, glucocorticoid discontinuation, and outcomes were retrospectively analyzed. RESULTS: Glucocorticoids could be discontinued in 19 (61%) patients during a median observation period of 105.5 (range, 17-221) months. Of these, 5 (26%), 12 (63%), and 18 (95%) patients could discontinue glucocorticoids in 3, 5, and 10 years from treatment initiation, respectively. Additionally, 18 of the 19 patients did not experience flares after glucocorticoid discontinuation during a median duration of 37.2 (7.2-106.8) months. Three of the nineteen patients achieved drug-free remission. At last follow-up, all patients achieved low disease activity with or without glucocorticoids and 19, 8, and 1 patient were receiving mycophenolate mofetil (MMF), MMF plus tacrolimus, and MMF plus ciclosporin A, respectively. Flares were observed in 15 patients during the observation period. MMF as initial immunosuppressant (P = 0.01) and shorter interval between therapy initiation and achieving maintenance prednisolone dose of 0.1-0.15 mg/kg/day (P = 0.001) were associated with significantly reduced flare risk. Femoral head necrosis was observed in two patients. CONCLUSION: Despite the small sample size, these results support glucocorticoid discontinuation as a therapeutic target in pediatric SLE.
Authors: Linda T Hiraki; Candace H Feldman; Jun Liu; Graciela S Alarcón; Michael A Fischer; Wolfgang C Winkelmayer; Karen H Costenbader Journal: Arthritis Rheum Date: 2012-08
Authors: Murray B Urowitz; Dafna D Gladman; Brian D M Tom; Dominique Ibañez; Vernon T Farewell Journal: J Rheumatol Date: 2008-09-15 Impact factor: 4.666
Authors: Ronald F van Vollenhoven; Marta Mosca; George Bertsias; David Isenberg; Annegret Kuhn; Kirsten Lerstrøm; Martin Aringer; Hendrika Bootsma; Dimitrios Boumpas; Ian N Bruce; Ricard Cervera; Ann Clarke; Nathalie Costedoat-Chalumeau; László Czirják; Ronald Derksen; Thomas Dörner; Caroline Gordon; Winfried Graninger; Frédéric Houssiau; Murat Inanc; Søren Jacobsen; David Jayne; Anna Jedryka-Goral; Adrian Levitsky; Roger Levy; Xavier Mariette; Eric Morand; Sandra Navarra; Irmgard Neumann; Anisur Rahman; Jozef Rovensky; Josef Smolen; Carlos Vasconcelos; Alexandre Voskuyl; Anne Voss; Helena Zakharova; Asad Zoma; Matthias Schneider Journal: Ann Rheum Dis Date: 2014-04-16 Impact factor: 19.103
Authors: Aimee O Hersh; Emily von Scheven; Jinoos Yazdany; Pantelis Panopalis; Laura Trupin; Laura Julian; Patricia Katz; Lindsey A Criswell; Edward Yelin Journal: Arthritis Rheum Date: 2009-01-15
Authors: F E Mackie; G Kainer; N Adib; C Boros; E J Elliott; R Fahy; J Munro; K Murray; A Rosenberg; B Wainstein; J B Ziegler; D Singh-Grewal Journal: Lupus Date: 2014-10-06 Impact factor: 2.911